Back to top

Image: Bigstock

Is Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now?

Read MoreHide Full Article

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.

Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.

In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.

One stock to keep an eye on is Rigel Pharmaceuticals (RIGL - Free Report) . RIGL is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A.

Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. RIGL has a P/S ratio of 1.64. This compares to its industry's average P/S of 3.45.

Finally, investors will want to recognize that RIGL has a P/CF ratio of 8.76. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. RIGL's P/CF compares to its industry's average P/CF of 9.44. Within the past 12 months, RIGL's P/CF has been as high as 96.38 and as low as -21.56, with a median of 9.13.

These are just a handful of the figures considered in Rigel Pharmaceuticals's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that RIGL is an impressive value stock right now.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Rigel Pharmaceuticals, Inc. (RIGL) - free report >>

Published in